Sumitomo Dainippon Pharma Stock Fundamentals
| DNPUFDelisted Stock | USD 4.37 0.00 0.00% |
Sumitomo Dainippon Pharma fundamentals help investors to digest information that contributes to Sumitomo Dainippon's financial success or failures. It also enables traders to predict the movement of Sumitomo Pink Sheet. The fundamental analysis module provides a way to measure Sumitomo Dainippon's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Sumitomo Dainippon pink sheet.
Sumitomo |
Sumitomo Dainippon Pharma Company Operating Margin Analysis
Sumitomo Dainippon's Operating Margin shows how much operating income a company makes on each dollar of sales. It is one of the profitability indicators which helps analysts to understand whether the firm is successful or not making money from everyday operations.
Current Sumitomo Dainippon Operating Margin | (0.03) % |
Most of Sumitomo Dainippon's fundamental indicators, such as Operating Margin, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Sumitomo Dainippon Pharma is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
A good Operating Margin is required for a company to be able to pay for its fixed costs or payout its debt, which implies that the higher the margin, the better. This ratio is most effective in evaluating the earning potential of a company over time when comparing it against a firm's competitors.
CompetitionBased on the recorded statements, Sumitomo Dainippon Pharma has an Operating Margin of -0.0273%. This is 99.92% lower than that of the Healthcare sector and significantly lower than that of the Drug Manufacturers—Specialty & Generic industry. The operating margin for all United States stocks is 99.5% lower than that of the firm.
Sumitomo Dainippon Pharma Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Sumitomo Dainippon's current stock value. Our valuation model uses many indicators to compare Sumitomo Dainippon value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Sumitomo Dainippon competition to find correlations between indicators driving Sumitomo Dainippon's intrinsic value. More Info.Sumitomo Dainippon Pharma is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Sumitomo Dainippon's earnings, one of the primary drivers of an investment's value.Sumitomo Operating Margin Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Sumitomo Dainippon's direct or indirect competition against its Operating Margin to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Sumitomo Dainippon could also be used in its relative valuation, which is a method of valuing Sumitomo Dainippon by comparing valuation metrics of similar companies.Sumitomo Dainippon is currently under evaluation in operating margin category among its peers.
Sumitomo Fundamentals
| Return On Equity | -0.0399 | |||
| Return On Asset | -0.0075 | |||
| Profit Margin | (0.01) % | |||
| Operating Margin | (0.03) % | |||
| Current Valuation | 2.85 B | |||
| Shares Outstanding | 397.29 M | |||
| Shares Owned By Insiders | 58.59 % | |||
| Shares Owned By Institutions | 19.60 % | |||
| Price To Earning | 4.79 X | |||
| Price To Book | 0.64 X | |||
| Price To Sales | 0.01 X | |||
| Revenue | 560.03 B | |||
| Gross Profit | 402.91 B | |||
| EBITDA | 124.36 B | |||
| Net Income | 56.41 B | |||
| Cash And Equivalents | 265.59 B | |||
| Cash Per Share | 668.50 X | |||
| Total Debt | 243.96 B | |||
| Debt To Equity | 0.36 % | |||
| Current Ratio | 1.74 X | |||
| Book Value Per Share | 1,599 X | |||
| Cash Flow From Operations | 31.24 B | |||
| Earnings Per Share | 0.24 X | |||
| Number Of Employees | 6.99 K | |||
| Beta | 0.31 | |||
| Market Capitalization | 2.64 B | |||
| Total Asset | 1.31 T | |||
| Retained Earnings | 349.13 B | |||
| Working Capital | 224.66 B | |||
| Current Asset | 384.35 B | |||
| Current Liabilities | 159.68 B | |||
| Annual Yield | 0.03 % | |||
| Net Asset | 1.31 T | |||
| Last Dividend Paid | 28.0 |
About Sumitomo Dainippon Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Sumitomo Dainippon Pharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Sumitomo Dainippon using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Sumitomo Dainippon Pharma based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.Sumitomo Pharma Co., Ltd. engages in the manufacture and sale of pharmaceuticals, food ingredients and additives, veterinary medicines, and others in Japan, North America, China, and internationally. Sumitomo Pharma Co., Ltd. is a subsidiary of Sumitomo Chemical Company, Limited. Dai Nippon operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on OTC Exchange. It employs 6987 people.
Currently Active Assets on Macroaxis
Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in employment. You can also try the Bond Analysis module to evaluate and analyze corporate bonds as a potential investment for your portfolios..
Other Consideration for investing in Sumitomo Pink Sheet
If you are still planning to invest in Sumitomo Dainippon Pharma check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Sumitomo Dainippon's history and understand the potential risks before investing.
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings |